As rivals march on, Novartis secures priority FDA review for sickle cell disease therapy
About a month after rival Global Blood Therapeutics $GBT unveiled positive pivotal data on its sickle cell disease drug, Novartis’ $NVS therapy for the blood disorder has been granted a speedy review by the FDA.
Touted by Novartis chief Vas Narasimhan as a potential blockbuster, the Swiss drugmaker’s drug, crizanlizumab, in January secured the FDA’s breakthrough therapy designation for its ability to prevent debilitatingly painful vaso-occlusive crisis (VOCs) for patients affected by the group of inherited red blood cell disorders that typically afflict those of African ancestry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.